Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720707 | 0.86 | CSNK2A1 (0.50) | CSNK2A1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL623349 | 0.82 | CSNK2A1 (0.52) | CSNK2A1BRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL1549076 | 0.80 | CSNK2A1 (0.53) | CSNK2A1BRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL3969507 | 0.79 | KDM4E (0.44) | CSNK2A1MEN1KMT2AKDM4EPOLB | |
| SCHEMBL27960925 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL1720594 | 0.79 | SMN1; SMN2 (0.52) | MEN1KMT2AALDH1A1KDM4ECA1 | |
| SCHEMBL3968709 | 0.79 | AKR1C3 (0.47) | KMT2AALDH1A1KDM4EHTTPOLB | |
| SCHEMBL14927072 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4EMCL1NOTUM | |
| SCHEMBL18280409 | 0.77 | CSNK2A1 (0.50) | CSNK2A1BRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL20943211 | 0.77 | CSNK2A1 (0.50) | CSNK2A1BRD4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966190-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007071348-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | CYP3A5, CYP3A43, CYP3A4 | CSNK2A1 1537/4885BRD4 950/4885MEN1 2037/4885 |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | CSNK2A1 2162/4885BRD4 95/4885MEN1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.